August 26, 2026

BSE Limited Floor 25, P. J. Towers Dalal Street, **Mumbai - 400 001** Scrip Code: **530019**	**National Stock Exchange of India Limited** Exchange Plaza Bandra Kurla Complex Bandra (E), **Mumbai - 400 051** Symbol: **JUBLPHARMA**

Sub: Proceedings of 48th Annual General Meeting held on Wednesday, August 26, 2026 pursuant to Regulation 30 and Voting Results along with Scrutinizer Report pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Dear Madam/Sirs,

We wish to inform you that the **48th Annual General Meeting ("AGM")** of **Jubilant Pharmova Limited** ("the Company") was held today, i.e., **Wednesday, August 26, 2026**, at **11:00 A.M. (IST)** through Video Conferencing / Other Audio Visual Means ("VC/OAVM") and concluded at **12:13 P.M. (IST)**.

All resolutions as mentioned in the Notice of the AGM were duly passed with the requisite majority.

Pursuant to the provisions of **Regulations 30 and 44** of the **SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**, we hereby submit the following documents:

1. **Annexure-1**: Summary of the proceedings of the 48th AGM of the Company.
2. **Annexure-2**: Details of voting results in respect of the 48th AGM held on Wednesday, August 26, 2026, through VC/OAVM, in compliance with Regulation 44(3).
3. **Annexure-3**: Consolidated Scrutinizer's Report dated August 26, 2026, on remote e-voting and e-voting conducted during the AGM, pursuant to Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014.

The above documents are being uploaded on the website of the Company at www.jubilantpharmova.com and National Securities Depositories Limited at www.evoting.nsdl.com.

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

We request you to take the same on records.

Thanking you,

Yours faithfully,
For Jubilant Pharmova Limited

Naresh Kapoor
Digitally signed by Naresh Kapoor
Date: 2026.08.26 19:33:43 +05'30'

Naresh Kapoor
Company Secretary

Encl: As above

CC:

National Securities Depository Limited
Trade World, A wing, 4th Floor, Kamala Mills Compound, Lower Parel, Mumbai-400013

Central Depository Services (India) Limited
Marathon Futurex, A-Wing, 25th Floor, NM Joshi Marg, Lower Parel, Mumbai-400013

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Annexure-1

Summary of Proceedings of the 48th Annual General Meeting of Jubilant Pharmova Limited

The 48th Annual General Meeting ("AGM") of Jubilant Pharmova Limited ("the Company") was held today, i.e., **Wednesday, August 26, 2026**, at **11:00 a.m. (IST)** through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM"), in accordance with the relevant circulars issued by the Ministry of Corporate Affairs ("MCA") and the Securities and Exchange Board of India ("SEBI").

The meeting commenced at **11:00 a.m. (IST)** and concluded at **12:13 p.m. (IST)**, including the time allowed for e-voting during the AGM. A total of **86 members**, representing **7,07,21,051 equity shares**, attended the AGM through VC. The following Directors were present through VC at the AGM:

S. No.	Name of the Director	Designation	Place of attending AGM through VC
1.	Mr. Shyam Sunder Bhartia	Chairman	New Delhi
2.	Mr. Hari Shanker Bhartia	Co-Chairman	Noida
3.	Mr. Priyavrat Bhartia	Managing Director	New Delhi
4.	Mr. Arjun Shanker Bhartia	Joint Managing Director	New Delhi
5.	Mr. Vivek Mehra	Independent Director and Chairperson of Audit Committee	London
6.	Ms. Shivpriya Nanda	Independent Director and Chairperson of Sustainability and CSR Committee	Gurugram
7.	Dr. Harsh Mahajan	Independent Director	New Delhi
8.	Mr. Arun Seth	Independent Director and Chairperson of the Stakeholders' Relationship Committee	New Delhi
9.	Mr. Shirish G. Belapure	Independent Director and Chairperson of the Quality Committee	Ahmedabad
10.	Mr. Sushil Kumar Roongta	Independent Director and Chairperson of the Nomination, Remuneration and Compensation Committee	Gurugram

In attendance:

S. No.	Name of the attendee	Designation	Place of attending AGM through VC
1.	Mr. Ashish Mukkirwar	Chief Financial officer	Noida
2.	Mr. Naresh Kapoor	Company Secretary	Noida

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Invitees:

S. No.	Name of the invitee	Designation	Attended through VC from
1.	Mr. Nitin Toshniwal	Partner, M/s. Walker Chandiok & Co., LLP, Chartered Accountants, Statutory Auditors.	New Delhi
2.	Mr. Kapil Taneja	Partner, M/s Sanjay Grover & Associates, Company Secretaries, Secretarial Auditors.	New Delhi
3.	Mr. Rupinder Singh Bhatia, Practicing Company Secretary (CP No. 2514)	Scrutinizer for the AGM.	New Delhi

Mr. Shyam Sunder Bhartia, Chairperson, welcomed all the members attending the 48th AGM. As the requisite quorum was present, he called the meeting to order.

The Chairperson introduced the Directors and Key Managerial Personnel participating in the meeting through Video Conferencing (VC). He also acknowledged the presence of Mr. Rupinder Singh Bhatia, Practising Company Secretary, as the Scrutinizer, along with representatives from the Statutory Auditors, *Walker Chandiok & Co LLP*, and the Secretarial Auditors, *M/s Sanjay Grover & Associates*, who attended the Annual General Meeting.

The Chairperson further informed the Members that Mr. Arun Seth, Chairperson of the Stakeholders' Relationship Committee, Mr. Sushil Kumar Roongta, Chairperson of the Nomination, Remuneration & Compensation Committee, and Mr. Vivek Mehra, Chairperson of the Audit Committee were present at the Meeting and available to address Members' queries pertaining to matters within the remit of their respective Committees.

The Members were also informed that the Company had taken all necessary steps, in accordance with applicable legal provisions, to enable participation by the members in the meeting through VC and to enable Members to participate in the AGM through VC and to cast their votes electronically on the resolutions set out in the Notice convening the AGM.

The Chairperson then delivered his address to the Members, highlighting, inter alia, the Company's financial and operational performance for the financial year 2025-26, the progress made towards Vision 2030, the launch of Line 3 at the Spokane facility, the transfer of the API business to Jubilant Biosys

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Limited, the economic outlook, initiatives relating to artificial intelligence and automation, the business outlook, performance for the first quarter of FY 2026-27, and the dividend recommendation.

The Chairperson further informed that the Statutory Registers along with the Certificate issued by the Secretarial Auditors pursuant to the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, and the other documents referred to in the AGM Notice were available for inspection electronically during the meeting. It was further informed that the Statutory Auditor's Report and Secretarial Auditor's Report for financial year 2025-26 does not contain any qualification, observation, adverse remark or disclaimer. With the consent of the members, the Notice convening the AGM for the financial year ended March 31, 2026, was taken as read.

The Chairperson further informed the members that the Company had provided remote e-voting facility to the members holding shares on the **Cut-off date i.e. Wednesday, August 19, 2026 (which started at 9:00 a.m. (IST) on Sunday, August 23, 2026 and ended at 5:00 p.m. (IST) on Tuesday, August 25, 2026)** to cast their votes on all the resolutions set forth in the AGM Notice. Members who were participating in the meeting and had not casted their votes through remote e-voting, were provided an opportunity to cast their votes through e-voting at the meeting.

The following items as stated in the notice of the 48th AGM were considered at the meeting:

Item No.	Particulars	Type of Resolutions
ORDINARY BUSINESS		
1.	To receive, consider and adopt: (a) the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026 together with the Reports of the Board of Directors and the Auditors thereon; and (b) the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026 together with the Report of the Auditors thereon.	Ordinary Resolution
2.	To declare a Dividend of Rs. 5 per equity share of the face value of Re. 1 each for the Financial Year ended March 31, 2026.	Ordinary Resolution

Mr. Shyam S. Bhartia, Chairperson, being interested in agenda item no. 3 and 4, requested Mr. Sushil Kumar Roongta, Chairperson of the Nomination, Remuneration & Compensation Committee to chair the meeting for these agenda items. Thereafter, Mr. Sushil Kumar Roongta took the chair.

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

JUBILANT PHARMOVA

Item No.	Particulars	Type of Resolutions
ORDINARY BUSINESS		
3.	To appoint a Director in place of Mr. Hari S. Bhartia [DIN: 00010499], who retires by rotation and, being eligible, offers himself for re-appointment.	Ordinary Resolution
4.	To appoint a Director in place of Mr. Arjun Shanker Bhartia [DIN: 03019690], who retires by rotation and, being eligible, offers himself for re-appointment.	Ordinary Resolution

Thereafter, Mr. Sushil Kumar Roongta, invited Mr. Shyam Sunder Bhartia to resume the chair.

The Members who had pre-registered themselves as speakers were given the opportunity to ask questions and express their views. Mr. Ashish Mukkirwar, Chief Financial Officer of the Company, responded to the shareholders' queries. Members were further informed that in case of any additional queries, they may please write to the Company Secretary or email the Company at investors@jubl.com.

Thereafter, it was announced that the e-Voting on the NSDL platform shall be available for next 30 minutes. The Board of Directors had appointed Mr. Rupinder Singh Bhatia, Practicing Company Secretary (CP No. 2514) as Scrutinizer to scrutinize the process of e-voting during the AGM and remote e-voting held before the AGM in a fair and transparent manner. It was also informed that the consolidated results of remote e-Voting and e-Voting at the AGM shall be declared within two working days from the conclusion of the meeting. The results, along with the Scrutinizer's Report, shall be placed on the website of the Company (www.jubilantpharmova.com), NSDL (www.evoting.nsdl.com), at the registered office and the corporate office of the Company and shall be communicated to Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited.

The meeting concluded with a vote of thanks to the Chair.

After the conclusion of the meeting, the Scrutinizer carried out the scrutiny of votes and submitted his Consolidated Scrutinizer's Report to the Chairperson. The Chairperson authorised the Company Secretary to accept and countersign the Report and declare the results. As per Consolidated Scrutinizer's Report on remote e-Voting and e-Voting at AGM, all the resolutions as mentioned in the Notice of AGM, were declared as passed with the requisite majority.

This is for your information and records.

Thanking you,

Yours Faithfully,
For Jubilant Pharmova Limited
Naresh Kapoor
Digitally signed by Naresh Kapoor
Date: 2026.08.26 19:57:24 +05'30'
Naresh Kapoor
Company Secretary
ACS -11782

A Jubilant Bhartia Company
Our Values
INSPIRE CONFIDENCE
ALWAYS STRETCH
NURTURE INNOVATION
EXCELLENT QUALITY

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

CHAIRMAN'S SPEECH

Dear Shareholders,

It gives me an immense pleasure to welcome you to the 48th Annual General Meeting of Jubilant Pharmova Limited. I, thank you for your continued trust and support.

FY26 was a year of purposeful progress for your Company. Against a backdrop of evolving market dynamics, geopolitical uncertainties, regulatory complexities and a rapidly transforming healthcare landscape, we remained focused on execution, innovation and long-term value creation. Guided by our **Vision 2030**, we continued to strengthen our leadership positions, expand our manufacturing and research capabilities, advance our innovation pipeline and deliver solutions that improve patient outcomes globally.

Jubilant Pharmova today is a global, integrated pharmaceutical company advancing healthcare through science, technology and precision execution. Our diversified portfolio spans six businesses, each with a differentiated position in its respective market:

- **In Radiopharmaceuticals,** we are an innovation leader in the U.S. cardiac PET imaging market through our Ruby-Fill® product and maintain leadership in our SPECT imaging portfolio.
- **In Radiopharmacies,** we operate the second-largest radiopharmacy network in the U.S., serving more than 1,800 hospitals.
- **In Allergy Immunotherapy,** we are the second-largest player in the U.S. allergenic extract market and the sole supplier of Venom Immunotherapy in the U.S.
- **In CDMO Sterile Injectables,** we are a leading contract manufacturer in North America, serving major global innovator pharmaceutical companies.
- **In CRDMO,** we are a leading integrated drug discovery player in India and an established API player with more than 100 APIs.
- **In Generics,** we have a presence in more than 50 countries and are building a growing, profitable and agile business.
- **In Proprietary Novel Drugs,** as a clinical-stage precision therapeutics company, we are addressing unmet medical needs through the development of easy-to-use oral therapies for difficult-to-treat cancers and autoimmune diseases.

Today, I will share the key highlights of our financial and strategic progress in FY26, the outlook for the pharmaceutical industry, our future growth strategy and our performance in Q1 FY27.

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Financial and Strategic Progress in FY26

FY26 tested the resilience of businesses worldwide. Intense competition, geopolitical uncertainties and operational challenges created a demanding environment. Despite these headwinds, Jubilant Pharmova delivered strong operational performance and continued to execute strategic initiatives that move us closer to our Vision 2030.

Consolidated revenue from operations grew **14% to ₹83 billion**, driven by broad-based growth across businesses and supported by incremental contributions from Line 3 in our CDMO Sterile Injectables business. EBITDA increased **8% to ₹13 billion**, while Normalised Profit After Tax grew **7% to ₹4 billion**.

Our Net Debt-to-EBITDA ratio increased modestly from **1.1x to 1.3x**, reflecting disciplined investments in growth-oriented capital expenditure that will support future earnings and value creation.

Our Radiopharmaceuticals business continued to strengthen its market position. We maintained our leadership in the SPECT imaging product portfolio while significantly expanding the installed base of Ruby-Fill®, driving market share gains. The business delivered a robust profitability, with **EBITDA margins of 41% in FY26**.

In our Radiopharmacy business, we partnered with Novartis to distribute Pluvicto®, an important radioligand therapy for prostate cancer patients. We also continued our investment programme for six PET manufacturing facilities, positioning the business to benefit from the growing adoption of radiopharmaceuticals and precision diagnostics.

Our Allergy Immunotherapy business sustained its growth momentum across the U.S. and international markets. Continued customer engagement, market expansion initiatives and our differentiated product portfolio supported strong operating performance, with **EBITDA margins of 35%**.

FY26 was a landmark year for our CDMO Sterile Injectables business. Revenue grew **38%**, while EBITDA increased **8% year-on-year**.

Following the successful launch of Line 3 at our Spokane facility, we witnessed a strong revenue ramp-up. Technology transfers for more than ten products across multiple formats and vial sizes are currently underway.

A particularly significant achievement was onboarding one of the world's largest oncology products onto Line 3. This reflects the confidence global pharmaceutical innovators place in our capabilities and reinforces our position as a trusted partner for complex sterile injectable manufacturing.

Line 4 at Spokane remains on track and will further strengthen our capabilities in biologics and complex sterile products. At Montreal, construction of Line 5 is progressing according to plan and is expected to begin contributing revenue from FY29 onward.

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

We also made substantial progress in strengthening quality systems and manufacturing processes at our Montreal facility. Following FDA observations and evolving global cGMP expectations for sterile manufacturing, we implemented comprehensive corrective and preventive actions, reinforcing our commitment to quality, compliance and operational excellence.

Our CRDMO business delivered another year of strong growth, with revenue increasing **15%** and EBITDA increasing **11%**.

We deepened relationships with global pharmaceutical and biotechnology customers while expanding our capabilities across the drug discovery and development value chain. Our strategic partnership with Pierre Fabre has enhanced our footprint in biologics and antibody-drug conjugates, two important and rapidly growing areas of pharmaceutical innovation.

During the year, we also completed the transfer of our API business to Jubilant Biosys Limited, creating a more integrated and synergistic platform for future growth.

The Generics business delivered a significant improvement in profitability. Revenue grew **13%**, while EBITDA increased **250%**.

We launched four products in the U.S. market and several products across international markets. Product supplies from our Roorkee facility to the U.S. market continued to ramp up steadily, complemented by supplies through contract manufacturing partners.

These initiatives are helping us build a more agile, diversified and profitable Generics business.

Our Proprietary Novel Drugs business continues to make encouraging progress. Clinical trials for our lead programmes, **JBI-802 and JBI-778**, are progressing as planned.

We are particularly encouraged by the preliminary data from the JBI-802 study, which has demonstrated rapid and durable, dose-dependent platelet normalisation in patients with Essential Thrombocythemia in Australia.

These developments reinforce our belief that precision therapeutics represents a significant long-term opportunity for Jubilant Pharmova and has the potential to create meaningful value for patients and shareholders.

Beyond financial performance, we continue to make meaningful progress in our sustainability journey. We are increasing the adoption of renewable energy across our facilities to reduce operating costs and carbon emissions. At the same time, we are embracing advanced technologies, including **Artificial Intelligence and Automation**, to improve manufacturing yields, enhance product quality, strengthen customer experience and drive productivity.

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

I am also pleased to share that both Jubilant Pharmova India and Jubilant Radiopharmacies USA were certified as **Great Place to Work®**, reflecting our commitment to creating a culture where our people can thrive.

Industry Outlook

The global pharmaceutical industry continues to evolve rapidly, creating significant opportunities for companies with differentiated capabilities and strong execution.

The U.S. pharmaceutical market expanded significantly in 2025, driven by growth in oncology, immunology and endocrinology therapies. The remarkable success of GLP-1 therapies has reshaped healthcare markets and triggered substantial investments in manufacturing and innovation.

In 2026, the industry faces a more complex operating environment shaped by large patent expirations, implementation of federal drug price negotiations and ongoing geopolitical shifts. At the same time, pharmaceutical companies continue to accelerate efforts towards friendshoring, strategic onshoring and supply-chain resilience.

We believe several long-term trends will continue to create growth opportunities:

- Expansion of radiopharmaceuticals
- Increasing focus on antibody-drug conjugates and cell-based therapies
- Growing outsourcing by pharmaceutical innovators
- Rise of precision medicine
- Greater deployment of AI-enabled drug discovery

Future Business Outlook

Looking ahead, our strategy remains focused on creating sustainable long-term growth across all our businesses.

In Radiopharmaceuticals, We will continue expanding the Ruby-Fill® installed base while advancing new PET and SPECT imaging products targeted for launch during FY28 and FY29. We are also preparing for the planned NDA submission for MIBG following completion of Phase 2 clinical development activities.

In Radiopharmacies, Growing adoption of PET diagnostics and therapeutic radiopharmaceuticals presents a significant opportunity. Our six PET manufacturing facilities are expected to become operational beginning FY28 and will support future growth.

In Allergy Immunotherapy, We will continue expanding awareness and market penetration for Venom Immunotherapy while working to grow our presence in Europe.

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Within CDMO Sterile Injectables, Line 3 is expected to transition increasingly towards commercial production in FY27. Line 4 is scheduled to commence technology transfers in FY27 and commercial manufacturing in FY28. Together with Line 5 at Montreal, these facilities will significantly enhance our ability to serve global innovator pharmaceutical companies.

The outlook of **CRDMO** remains positive as pharmaceutical and biotechnology companies increasingly outsource research, development and manufacturing activities.

In Generics, We expect multiple product launches across the U.S. and international markets, supporting continued growth and improved profitability.

For Proprietary Novel Drugs, We look forward to key clinical milestones and interim data readouts from the Phase I/II study of JBI-802.

Q1 FY27 Performance

We have started FY27 on a strong revenue footing. During the first quarter, revenue increased **17% year-on-year to approximately ₹22 billion**, reflecting healthy growth across businesses. EBITDA stood at **₹2.7 billion**.

Profitability was impacted by the temporary unavailability of high-margin SPECT radiopharmaceutical products and incremental remediation costs at the Montreal facility.

However, significant progress has been made towards restoring normal production. Media fills have been successfully completed, commercial batch manufacturing has commenced, and we expect product releases during **Q2 FY27**, with production normalising in the second half of the year.

As production stabilises, we expect margins to strengthen meaningfully in **H2 FY27**.

Dividend

The Board of Directors has recommended a dividend of **₹5 per equity share of ₹1 each** for the financial year ended March 31, 2026.

Conclusion

As we look ahead, I am confident that Jubilant Pharmova is entering a new phase of growth. Our diversified portfolio, leadership positions in attractive healthcare markets, expanding manufacturing capabilities, robust innovation pipeline and unwavering commitment to quality provide a strong foundation for long-term value creation.

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

The strategic investments we are making today in radiopharmaceuticals, sterile injectables and CRDMO are shaping the future of our Company and creating a platform for sustainable growth for many years to come.

At Jubilant Pharmova, our purpose remains clear: **to improve patient lives through science and innovation while creating enduring value for all stakeholders.**

Vision 2030 continues to be our North Star, guiding our efforts to build a stronger and more future-ready Jubilant Pharmova. We are now delivering revenue growth of **over 12%**, consistent with the trajectory required to achieve our long-term revenue targets. **FY28 is expected to be an inflection year**, driven by new radiopharmaceutical products, commercial production from Line 3 and technology-transfer revenues from Line 4. These developments are expected to support healthy margin expansion through FY30.

As profitability improves and capex intensity moderates, we also expect stronger cash flows, improved RoCE and a gradual reduction in debt. Together, these trends reinforce our confidence in delivering Vision 2030 and creating sustainable value for our shareholders.

On behalf of the Board of Directors, I extend my sincere gratitude to our shareholders for your continued trust and support.

I thank our customers, partners, lenders, regulators and communities for their continued confidence in us. Above all, I thank our employees across the world whose dedication, passion and commitment make our success possible.

Together, we have built a resilient organisation. Together, we are creating a stronger future. And together, we will continue advancing healthcare and delivering sustainable value for generations to come.

I would like to conclude by a vote of appreciation to all of our valued shareholders who have joined us today and the larger investor community for supporting us in our business endeavors.

Thank you.

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Annexure - 2

Jubilant Pharmova Limited								
Voting Results of 48th Annual General Meeting (AGM)								
Details of AGM and remote e-voting results as per Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in respect of the following resolutions:								
Date of the Annual General Meeting								26.08.2026
Total number of shareholders on Cut-off date i.e. August 19, 2026								85192
No. of shareholders present in the meeting either in person or through Proxy: Promoters and Promoters Group: Public:								NA
No. of Shareholders attended the meeting through Video Conferencing Promoters and Promoters Group: Public:								9 77
1. Ordinary Resolution: Consideration and adoption of: (a) the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026 together with the Reports of the Board of Directors and the Auditors thereon; and (b) the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026 together with the Report of the Auditors thereon.								
Whether promoter/ promoter group are interested in the agenda/resolution?					**No**			
Category	**Mode of Voting**	**No. of shares held**	**No. of votes polled**	**% votes polled on outstanding shares**	**No. of votes - in favour**	**No. of votes - in Against**	**% of votes - in favour**	**% of votes - in Against**
		(1)	**(2)**	**(3)=[(2)/(1)]*100**	**(4)**	**(5)**	**(6)=[(4)/(2)]*100**	**(7)=[(5)/(2)]*100**
Promoter and Promoter Group	E-voting	75938622	70708167	93.1123	70708167	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot(if applicable)		0	0.0000	0	0	0.0000	0.0000

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

	Total	**75938622**	**70708167**	**93.1123**	**70708167**	**0**	**100.0000**	**0.0000**
Public Institutions	E-voting	46946977	35712119	76.0690	35712119	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot(if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	**46946977**	**35712119**	**76.0690**	**35712119**	**0**	**100.0000**	**0.0000**
Public Non-Institutions	E-voting	36395540	10415236	28.6168	10414733	503	99.9952	0.0048
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot(if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	**36395540**	**10415236**	**28.6168**	**10414733**	**503**	**99.9952**	**0.0048**
Total		**159281139**	**116835522**	**73.3518**	**116835019**	**503**	**99.9996**	**0.0004**

2. **Ordinary Resolution:** Declaration of dividend of Rs. 5 per equity share of the face value of Re. 1 each for the financial year ended March 31, 2026.

Whether promoter/ promoter group are interested in the agenda/resolution?					**No**			
Category	**Mode of Voting**	**No. of shares held**	**No. of votes polled**	**% votes polled on outstanding shares**	**No. of votes - in favour**	**No. of votes - in Against**	**% of votes - in favour**	**% of votes - in Against**
		(1)	**(2)**	**(3)=[(2)/(1)]*100**	**(4)**	**(5)**	**(6)=[(4)/(2)]*100**	**(7)=[(5)/(2)]*100**
Promoter and Promoter Group	E-voting	75938622	70708167	93.1123	70708167	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot(if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	**75938622**	**70708167**	**93.1123**	**70708167**	**0**	**100.0000**	**0.0000**
Public Institutions	E-voting	46946977	35782368	76.2187	35782368	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot(if applicable)		0	0.0000	0	0	0.0000	0.0000

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Category	Mode of Voting	No. of shares held	No. of votes polled	% votes polled on outstanding shares	No. of votes - in favour	No. of votes - in Against	% of votes - in favour	% of votes - in Against
	Total	**46946977**	**35782368**	**76.2187**	**35782368**	**0**	**100.0000**	**0.0000**
Public Non-Institutions	E-voting	36395540	10415236	28.6168	10414913	323	99.9969	0.0031
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot(if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	**36395540**	**10415236**	**28.6168**	**10414913**	**323**	**99.9969**	**0.0031**
Total		**159281139**	**116905771**	**73.3959**	**116905448**	**323**	**99.9997**	**0.0003**

3. Ordinary Resolution: To appoint a Director in place of Mr. Hari S. Bhartia (DIN: 00010499), who retires by rotation and, being eligible, offers himself for re-appointment.

Whether promoter/ promoter group are interested in the agenda/resolution?					**No**			
Category	Mode of Voting	No. of shares held	No. of votes polled	% votes polled on outstanding shares	No. of votes - in favour	No. of votes - in Against	% of votes - in favour	% of votes - in Against
		(1)	(2)	(3)=[(2)/(1)]*100	(4)	(5)	(6)=[(4)/(2)]*100	(7)=[(5)/(2)]*100
Promoter and Promoter Group	E-voting	75938622	70708167	93.1123	70708167	0	100	0
	Poll		0	0.0000	0	0	0	0
	Postal Ballot(if applicable)		0	0.0000	0	0	0	0
	Total	**75938622**	**70708167**	**93.1123**	**70708167**	**0**	**100**	**0**
Public Institutions	E-voting	46946977	35782368	76.2187	35152944	629424	98.2410	1.7590
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot(if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	**46946977**	**35782368**	**76.2187**	**35152944**	**629424**	**98.2410**	**1.7590**
	E-voting	36395540	10415236	28.6168	10414643	593	99.9943	0.0057
	Poll		0	0.0000	0	0	0.0000	0.0000

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Public Non-Institutions	Postal Ballot(if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	**36395540**	**10415236**	**28.6168**	**10414643**	**593**	**99.9943**	**0.0057**
Total		**159281139**	**116905771**	**73.3959**	**116275754**	**630017**	**99.4611**	**0.5389**

4. Ordinary Resolution: To appoint a Director in place of Mr. Arjun Shanker Bhartia (DIN: 03019690), who retires by rotation and, being eligible, offers himself for re-appointment.

Whether promoter/ promoter group are interested in the agenda/resolution?					**No**			
Category	**Mode of Voting**	**No. of shares held**	**No. of votes polled**	**% votes polled on outstanding shares**	**No. of votes - in favour**	**No. of votes - in Against**	**% of votes - in favour**	**% of votes - in Against**
		(1)	(2)	(3)=[(2)/(1)]*100	(4)	(5)	(6)=[(4)/(2)]*100	(7)=[(5)/(2)]*100
Promoter and Promoter Group	E-voting	75938622	70708167	93.1123	70708167	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot(if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	**75938622**	**70708167**	**93.1123**	**70708167**	**0**	**100.0000**	**0.0000**
Public Institutions	E-voting	46946977	35782368	76.2187	35362228	420140	98.8258	1.1742
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot(if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	**46946977**	**35782368**	**76.2187**	**35362228**	**420140**	**98.8258**	**1.1742**
Public Non-Institutions	E-voting	36395540	10415236	28.6168	10414643	593	99.9943	0.0057
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot(if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	**36395540**	**10415236**	**28.6168**	**10414643**	**593**	**99.9943**	**0.0057**
Total		**159281139**	**116905771**	**73.3959**	**116485038**	**420733**	**99.6401**	**0.3599**

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Rupinder Singh Bhatia
M.A., F.C.S.
Company Secretary in Practice
CP No.: 2514
Peer Review No.:1496/2021

J-17 (Basement),Lajpat Nagar III,
New Delhi-110024.
Ph. 011-41078605 M: 09811113545
PAN. AAFPB5130M
GST No.- 07AAFPB5130M1ZX
Email: bhatia_r_s@hotmail.com
Service Category:-Company Secretary in Practice

To,
The Chairman,
JUBILANT PHARMOVA LIMITED
(CIN: L24116UP1978PLC004624)
Registered Office: Bhartiagram, Gajraula,
District Amroha - 244 223,
Uttar Pradesh, India

Dear Sir,

I, Rupinder Singh Bhatia, Practicing Company Secretary, was appointed as the Scrutinizer by the Board of Directors of Jubilant Pharmova Limited at its meeting held on May 22, 2026, pursuant to section 108 and 109 of The Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended from time to time, for scrutinizing the remote e-voting process and voting conducted during the 48th Annual General Meeting of the Company held on August 26, 2026.

In this regard, I am pleased to submit my Report, which is comprehensive and self- explanatory in all respects.

Rupinder Singh Bhatia
Company Secretary in Practice
CP No.- 2514
Peer Review: 1496/2021

R.S. BHATIA ★ DELHI ★ COMPANY SECRETARY

Date: August 26, 2026
Place: New Delhi
UDIN F002599H001229605

Rupinder Singh Bhatia
M.A., F.C.S.
Company Secretary in Practice
CP No.: 2514
Peer Review No.:1496/2021

J-17 (Basement),Lajpat Nagar III,
New Delhi-110024.
Ph. 011-41078605 M: 09811113545
PAN. AAFPB5130M
GST No.- 07AAFPB5130M1ZX
Email: bhatia_r_s@hotmail.com
Service Category:-Company Secretary in Practice

FORM No. MGT-13
Report of Scrutinizer
(Pursuant to the Section 109 of The Companies Act, 2013 and rule 21(2) of the Companies (Management and Administration) Rules, 2014)

Name of the Company	Jubilant Pharmova Limited
Meeting	48th Annual General Meeting
Day, Date & Time	Wednesday, August 26, 2026 at 11:00 a.m. (IST)
Deemed Venue	Bhartiagram, Gajraula, District Amroha - 244 223
Mode	Video Conferencing ("VC")

1. **Appointment as Scrutinizer**

I, Rupinder Singh Bhatia, Practising Company Secretary,wasappointed as Scrutinizer by the Board of Directors of Jubilant Pharmova limited at its meeting held on May 22, 2206, for the purpose of scrutinizing the process of voting through electronic means i.e. remote e-voting and e-voting at the time of 48th AGM on the resolutions contained in the notice of AGM dated July 16, 2026 issued in accordance with General Circular No. 3/ 2025 dated September 22, 2025 ("MCA Circular") issued by the Ministry of Corporate Affairs and relevant circular issued by the Securities and Exchange Board of India, calling the 48th Annual General Meeting of its Equity Shareholders ("the Meeting" /"AGM") through VC / OAVM. The AGM was convened on Wednesday, August 26, 2026 at 11:00 a.m. (IST) through VC / OAVM.

The said appointment as Scrutinizer is under the provisions of Section 108 of the Companies Act, 2013 ("the Act") read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended ("the Rules").

As the Scrutinizer, I have scrutinized:

(i) process of e-voting remotely, before the AGM, using an electronic voting system on the dates referred to in the Notice calling the AGM ("remote e-voting"); and
(ii) process of e-voting at the AGM through electronic voting system ("e-voting").

My responsibility as a scrutinizer was to ensure that the voting process was conducted in a fair and transparent manner and submit a report on the voting on the resolutions based on the reports generated from the electronic voting system of NSDL (agency for providing the remote e-voting facility and e-voting system during the AGM).

2. **Dispatch of Notice convening the AGM**

2.1 The Company informed that on the basis of the list of members and Beneficial Owners made available by Alankit Assignments Limited, the Registrar and Transfer Agent of the Company, the Company completed dispatch of Notice of AGM on August 1, 2026 electronically to shareholders through the NSDL, whose email ids were available with Alankit Assignments Limited or the Company or the Depository Participants and a letter

R.S. BHATIA DELHI COMPANY SECRETARY

Rupinder Singh Bhatia

M.A., F.C.S.
Company Secretary in Practice
CP No.: 2514
Peer Review No.:1496/2021

J-17 (Basement),Lajpat Nagar III,
New Delhi-110024.
Ph. 011-41078605 M: 09811113545
PAN. AAFPB5130M
GST No.- 07AAFPB5130M1ZX
Email: bhatia_r_s@hotmail.com
Service Category:-Company Secretary in Practice

providing web-link alongwith QR code of AGM notice and Annual report for FY 2025-26 through registered post to shareholders who have not registered their email ids.

2.2 Pursuant to MCA Circular as mentioned above issued by the Ministry of Corporate Affairs and as per the provisions of Rule 20 of The Companies (Management & Administration) Rules, 2014, and Regulation 47 of The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, newspaper advertisements with respect to dispatch of Notice of AGM and Annual Report for FY 2025-26 were published in Financial Express (English newspaper) and Hindustan & Jansatta (Hindi newspaper) on August 2, 2026 specifying the date and time of the AGM, availability of the notice on Company's website and website of the Stock Exchanges, manner of registration of e-mail ids by the members (both physical and demat) who wants to register their e-mail ids with the Company, manner of voting through remote-voting or through e-voting system at the AGM etc.

As informed by the management, the Notice of the 48th AGM and Annual Report was published on the website of the Company at www.jubilantpharmova.com and also on the website NSDL at www.evoting.nsdl.com. The same was also submitted to BSE Limited and National Stock Exchange of India Limited on August 1, 2026.

3. **Cut-off Date**

Voting rights of the members were reckoned as on Wednesday, August 19, 2026, being the cut-off date for the purpose of deciding the entitlements of members for remote e-voting and e-voting during the AGM.

4. **Process of Remote e-voting and e-voting during AGM**

4.1 The remote e-voting period commenced on Sunday, August 23, 2026 at 09:00 A.M. (IST) and ended on Tuesday, August 25, 2026 at 05:00 P.M. (IST) via e-voting platform on the designated portal webpage provided by National Depository Services Limited.

4.2 The Company also provided e-voting facility to the Members who attended through VC/OAVM during the AGM to enable those Members to cast their votes, who had not cast their votes earlier through remote e-voting.

4.3 After the time fixed for closing of the e-voting by the Chairman, the electronic system recording the e-voting (e-votes) was locked by NSDL under my instructions.

4.4 The e-voting system was scrutinized on test check basis. The e-votes were reconciled with the records maintained by the Company / RTA and the authorizations lodged with the Company/ RTA on test check basis.

4.5 The e-votes cast were unblocked on Wednesday, August 26, 2026 after the conclusion of the AGM.

R.S. BHATIA
DELHI
COMPANY SECRETARY

Rupinder Singh Bhatia
M.A., F.C.S.
Company Secretary in Practice
CP No.: 2514
Peer Review No.:1496/2021

J-17 (Basement),Lajpat Nagar III,
New Delhi-110024.
Ph. 011-41078605 M: 09811113545
PAN. AAFPB5130M
GST No.- 07AAFPB5130M1ZX
Email: bhatia_r_s@hotmail.com
Service Category:-Company Secretary in Practice

5. **Attendance during AGM**

As reported by NSDL, 86 members attended the AGM through VC/OAVM. No physical presence of members was allowed at a common venue as per MCA Circulars.

6. **Counting Process**

After completion of e-voting during the AGM, the data of remote e-voting and e-voting was diligently scrutinized. Records were maintained containing the summary of results of remote e-voting and e-voting during AGM.

7. **Results**

7.1 The Voting pattern through remote e-voting and e-voting at AGM is given in **Annexure-A**.

7.2 Consolidated result with respect to each item as set out in the Notice of the AGM dated July 16, 2026 is enclosed as **Annexure - B.**

7.3 Based on the aforesaid results, I report that 4 Resolutions as set out in item Nos. 1 to 4 of the Notice of the AGM dated July 16, 2026 have been passed with the requisite majority.

8. The electronic data relating to remote e-voting and e-voting made at AGM have been handed over to Mr. Naresh Kapoor, Company Secretary and Compliance Officer, for preserving safely.

RSBhatia

Rupinder Singh Bhatia
Company Secretary in Practice
CP No.- 2514
Peer Review No.:1496/2021
Date: 26/08/2026
Place: New Delhi
UDIN: F002599H001229605

R.S. BHATIA ★ DELHI ★ COMPANY SECRETARY

Rupinder Singh Bhatia
M.A., F.C.S.
Company Secretary in Practice
CP No.: 2514
Peer Review No.:1496/2021

J-17 (Basement),Lajpat Nagar III,
New Delhi-110024.
Ph. 011-41078605 M: 09811113545
PAN. AAFPB5130M
GST No.- 07AAFPB5130M1ZX
Email: bhatia_r_s@hotmail.com
Service Category:-Company Secretary in Practice

Annexure-A

Resolution No.:- 1 Ordinary Resolution:

Consideration and adoption of:
(a) the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026 together with the Reports of the Board of Directors and the Auditors thereon; and
(b) the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026 together with the Report of the Auditors thereon

	Remote e-Voting		E-Voting at AGM		Total		Percentage
	Number	Votes	Number	Votes	Number	Votes	
Assent	315	11,67,52,069	8	82,950	323	11,68,35,019	99.9996
Dissent	4	503	0	0	4	503	0.0004
Total	**319**	**11,67,52,572**	**8**	**82,950**	**327**	**11,68,35,522**	**100**

Resolution No.:- 2 Ordinary Resolution
Declaration of Dividend of ₹5 per equity share of the face value of ₹1 each for the financial year ended March 31, 2026

	Remote e-Voting		E-Voting at AGM		Total		Percentage
	Number	Votes	Number	Votes	Number	Votes	
Assent	319	11,68,22,498	8	82,950	327	11,69,05,448	99.9997
Dissent	2	323	0	0	2	323	0.0003
Total	**321**	**11,68,22,821**	**8**	**82,950**	**329**	**11,69,05,771**	**100**

Resolution No.:- 3 Ordinary Resolution
Appointment of Mr. Hari S. Bhartia [DIN: 00010499], who retired by rotation at this meeting as a Director and being eligible offered himself for re-appointment.

	Remote e-Voting		E-Voting at AGM		Total		Percentage
	Number	Votes	Number	Votes	Number	Votes	
Assent	281	11,61,92,804	8	82,950	289	11,62,75,754	99.4611
Dissent	43	6,30,017	0	0	43	6,30,017	0.5389
Total	**324**	**11,68,22,821**	**8**	**82,950**	**332**	**11,69,05,771**	**100**

Resolution No.:- 4 Ordinary Resolution

R.S. BHATIA ★ DELHI ★ COMPANY SECRETARY

Rupinder Singh Bhatia
M.A., F.C.S.
Company Secretary in Practice
CP No.: 2514
Peer Review No.:1496/2021

J-17 (Basement),Lajpat Nagar III,
New Delhi-110024.
Ph. 011-41078605 M: 09811113545
PAN. AAFPB5130M
GST No.- 07AAFPB5130M1ZX
Email: bhatia_r_s@hotmail.com
Service Category:-Company Secretary in Practice

Appointment of Mr. Arjun Shanker Bhartia [DIN: 03019690], who retired by rotation at this meeting as a Director and being eligible offered himself for re-appointment

	Remote e-Voting		E-Voting at AGM		Total		Percentage
	Number	Votes	Number	Votes	Number	Votes	
Assent	291	11,64,02,088	8	82,950	299	11,64,85,038	99.6401
Dissent	34	4,20,733	0	0	34	4,20,733	0.3599
Total	**325**	**11,68,22,821**	8	**82,950**	**333**	**11,69,05,771**	**100**

The detailed break up of voting in respect of above resolution is attached to this report and marked as **Annexure – B.**

R.S. BHATIA ★ DELHI ★ COMPANY SECRETARY

Rupinder Singh Bhatia
Scrutinizer
Company Secretary in Practice
CP No.: 2514
Peer Review: 1496/2021
Place: New Delhi
Date: 26/08/2026
UDIN: F002599H001229605

Witness 1

Name: Rihika
Address: Karhera, mohan nagar Gzb - 201007

Witness 2

Name: MOHD ANAS
Address: Shaheen Bagh N. Delhi - 110025

For Jubilant Pharmova Limited

Naresh Kapoor — Digitally signed by Naresh Kapoor Date: 2026.08.26 19:32:56 +05'30'

Name: Mr. Naresh Kapoor
Designation: Company Secretary
Membership No.: ACS 11782
Duly Authorized by Chairman of the 48th AGM of Jubilant Pharmova Limited

Rupinder Singh Bhatia
M.A., F.C.S.
Company Secretary in Practice
CP No.: 2514
Peer Review No.:1496/2021

J-17 (Basement),Lajpat Nagar III,
New Delhi-110024.
Ph. 011-41078605 M: 09811113545
PAN. AAFPB5130M
GST No.- 07AAFPB5130M1ZX
Email: bhatia_r_s@hotmail.com
Service Category:-Company Secretary in Practice

Annexure – B

A detailed summary of voting through e-voting is given herein below:

Resolution 1:

Voting through remote e-voting:			
Particulars	No. of e-voters	No. of equity shares	Paid up value of the equity shares (in Rs.)
a) Total votes received	327	11,68,35,522	11,68,35,522
b) Net valid votes cast	327	11,68,35,522	11,68,35,522
c) Invalid Votes	NA	NA	NA
d) Votes with assent for the resolution	323	11,68,35,019	11,68,35,019
e) Votes with dissent for the resolution	4	503	503

Resolution 2:

Voting through remote e-voting:			
Particulars	No. of e-voters	No. of equity shares	Paid up value of the equity shares (in Rs.)
a) Total votes received	329	11,69,05,771	11,69,05,771
b) Net valid votes cast	329	11,69,05,771	11,69,05,771
c) Invalid Votes	NA	NA	NA
d) Votes with assent for the resolution	327	11,69,05,448	11,69,05,448
e) Votes with dissent for the resolution	2	323	323

Resolution 3:

Voting through remote e-voting:			
Particulars	No. of e-voters	No. of equity shares	Paid up value of the equity shares (in Rs.)
a) Total votes received	332	11,69,05,771	11,69,05,771
b) Net valid votes cast	332	11,69,05,771	11,69,05,771
c) Invalid Votes	NA	NA	NA
d) Votes with assent for the resolution	289	11,62,75,754	11,62,75,754

R.S. BHATIA
DELHI
COMPANY SECRETARY

Rupinder Singh Bhatia

M.A., F.C.S.
Company Secretary in Practice
CP No.: 2514
Peer Review No.:1496/2021

J-17 (Basement),Lajpat Nagar III,
New Delhi-110024.
Ph. 011-41078605 M: 09811113545
PAN. AAFPB5130M
GST No.- 07AAFPB5130M1ZX
Email: bhatia_r_s@hotmail.com
Service Category:-Company Secretary in Practice

e) Votes with dissent for the resolution	43	6,30,017	6,30,017

Resolution 4:

Voting through remote e-voting:			
Particulars	No. of e-voters	No. of equity shares	Paid up value of the equity shares (in Rs.)
a) Total votes received	333	11,69,05,771	11,69,05,771
b) Net valid votes cast	333	11,69,05,771	11,69,05,771
c) Invalid Votes	NA	NA	NA
d) Votes with assent for the resolution	299	11,64,85,038	11,64,85,038
e) Votes with dissent for the resolution	34	4,20,733	4,20,733

R.S. BHATIA ★ DELHI ★ COMPANY SECRETARY